Daiichi Sankyo Company, Limited announced that it has launched its oral anticoagulant LixianaⓇ OD Tablets 15 mg, 30 mg and 60 mg (generic name: Edoxaban Tosilate Hydrate, date of manufacture and marketing approval: August 16, 2017; date of listing in NHI reimbursement price list in Japan: November 29, 2017) in Japan.
Lixianais a once daily oral anticoagulant that selectively, reversibly and directly inhibits FXa (activated blood coagulation factor X) which is involved in blood coagulation in blood vessels. Lixianahas the 3 indications of prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)], and prevention of VTE after major orthopedic surgery, and is currently widely used in the prevention and treatment of thromboembolism.
Daiichi Sankyo expects the addition of Lixiana OD Tablets, which are designed to be easy to take for elderly patients, to contribute greatly to increasing medication adherence* in patients requiring anticoagulant therapy.
Medication adherence: the extent to which patients actively follow a medication regimen as prescribed by their health care providers.
